Health Canada warns on counterfeit and unauthorized Ozempic and Mounjaro sellers

Health Canada issued advisory RA-81518 on September 11, 2026, warning that unauthorized and counterfeit versions of GLP-1 drugs like Ozempic and Mounjaro are being sold by retailers and online sellers, and telling Canadians to buy these medicines only from licensed pharmacies ^[1].

The warning arrives at an unusual moment in the Canadian market. Canada recently became the second country in the world, and the first in the G7, to authorize a generic version of semaglutide, the active ingredient in Ozempic, Wegovy, and Rybelsus ^[1]. As of early September, three of nine submitted generic semaglutide products had been approved by Health Canada, with Dr. Reddy's cleared first on April 28 and Apotex also shipping product, while eight more generic files remained under review ^[1]. That approval traces back to a business decision: Novo Nordisk stopped paying a roughly $250 Canadian annual patent maintenance fee in 2018, a lapse that patent expert Tahir Amin of the group I-MAK says could have kept the patent active until 2028 had Novo Nordisk chosen to renew it ^[1].

The pricing structure for these generics is tiered under Canada's pCPA system. The first generic to market is priced at 75% to 85% of the brand-name cost, and prices are set to fall to 35% of brand pricing once three or more generic competitors are on the market ^[1]. Novo Nordisk has responded by rolling out a savings card that aligns Ozempic's price with generics for uninsured Canadians outside Quebec, distributed through Rexall pharmacies ^[1]. Generic tirzepatide, the ingredient in Mounjaro and Zepbound, is also moving through the pipeline, with Sandoz estimating a monthly price of $200 to $400 for its proposed product, alongside renewed Health Canada warnings about unauthorized GLP-1 products ^[1].

Why it matters for patients

The combination of genuine price competition and a fast-moving generic rollout creates exactly the kind of confusion that counterfeit sellers can exploit. When real prices are falling and multiple new products are entering pharmacies, it becomes harder for patients to judge whether a lower price from an unfamiliar seller reflects a legitimate generic or a fake product. Health Canada's advisory does not detail specific harms tied to particular counterfeit batches in the sources reviewed here, but the core instruction is that consumers should obtain these medications only through licensed pharmacies ^[1].

For patients already using Ozempic, Wegovy, Rybelsus, Mounjaro, or Zepbound, the practical takeaway is that the Canadian market now includes both approved generic semaglutide and unauthorized copies circulating outside the regulated pharmacy system, and telling them apart from packaging or price alone is not something the sources say is reliable. It is not yet known from these sources how widespread the counterfeit problem is, what specific products or lot numbers have been flagged, or what health effects, if any, have been reported.

What happens next

Health Canada continues to review eight additional generic semaglutide submissions as of early September 2026 ^[1]. Generic tirzepatide products, including one from Sandoz, are still in earlier stages, with pricing estimates but no confirmed Canadian launch date noted in the sources ^[1]. Industry analysts expect prices to keep falling as more generic entrants clear review and the pCPA's lower pricing tier, triggered once three or more generics are available, takes effect ^[1]. Novo Nordisk has forecast a 5% to 13% decline in its 2026 sales tied partly to this generic competition, while Eli Lilly has projected $80 billion to $83 billion in 2026 sales ^[1].